(Q37901437)

25 August 2017

1 reference

title

World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management (English)

1 reference

World Health Organization

25 August 2017

main subject

0 references

diagnosis

0 references

author name string

Jason Gotlib

series ordinal

1

1 reference

25 August 2017

language of work or name

1 reference

1 August 2011

1 reference

American Journal of Hematology

25 August 2017

published in

1 reference

25 August 2017

volume

86

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

677-688

1 reference

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence.

25 August 2017

cites work

1 reference

Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias

21 January 2018

1 reference

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature

21 January 2018

1 reference

t(5;9)(q11;q34): a novel familial translocation involving Abelson oncogene and association with hypereosinophilia.

21 January 2018

1 reference

Idiopathic hypereosinophilic syndrome in children: report of a 7-year-old boy with FIP1L1-PDGFRA rearrangement.

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

21 January 2018

1 reference

Eosinophilia: secondary, clonal and idiopathic

21 January 2018

1 reference

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

21 January 2018

1 reference

NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations

21 January 2018

1 reference

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

21 January 2018

1 reference

The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.

21 January 2018

1 reference

Clinical and echocardiographic features of hypereosinophilic syndromes

21 January 2018

1 reference

Carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review

21 January 2018

1 reference

Eosinophilic gastroenteritis: a review.

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

21 January 2018

1 reference

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)

21 January 2018

1 reference

The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP

21 January 2018

1 reference

Recent advances in pathogenesis and management of hypereosinophilic syndromes

21 January 2018

1 reference

Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome

21 January 2018

1 reference

Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia.

21 January 2018

1 reference

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations

21 January 2018

1 reference

T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome

21 January 2018

1 reference

Eosinophilia associated with clonal T-cell proliferation

21 January 2018

1 reference

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

21 January 2018

1 reference

Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia

21 January 2018

1 reference

The eosinophilias, including the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Treatment of hypereosinophilic syndrome with imatinib mesilate

21 January 2018

1 reference

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

21 January 2018

1 reference

Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

21 January 2018

1 reference

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

21 January 2018

1 reference

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing

21 January 2018

1 reference

Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia

21 January 2018

1 reference

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib

21 January 2018

1 reference

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

21 January 2018

1 reference

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

21 January 2018

1 reference

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo

21 January 2018

1 reference

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

21 January 2018

1 reference

Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia

21 January 2018

1 reference

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders

21 January 2018

1 reference

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2

21 January 2018

1 reference

FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.

21 January 2018

1 reference

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

21 January 2018

1 reference

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

21 January 2018

1 reference

Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation

21 January 2018

1 reference

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.

21 January 2018

1 reference

Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases.

21 January 2018

1 reference

Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review

21 January 2018

1 reference

Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis

21 January 2018

1 reference

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Successful cyclophosphamide therapy in recurrent eosinophilic colitis associated with hypereosinophilic syndrome

21 January 2018

1 reference

Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide.

21 January 2018

1 reference

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Cyclosporin for hypereosinophilic syndrome

21 January 2018

1 reference

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome

21 January 2018

1 reference

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome.

21 January 2018

1 reference

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

21 January 2018

1 reference

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

21 January 2018

1 reference

Treatment of patients with the hypereosinophilic syndrome with mepolizumab

21 January 2018

1 reference

The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease

21 January 2018

1 reference

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.

21 January 2018

1 reference

Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia

21 January 2018

1 reference

Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome

21 January 2018

1 reference

Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis.

21 January 2018

1 reference

Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome

21 January 2018

1 reference

Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis

21 January 2018

1 reference

Neurologic dysfunction in the idiopathic hypereosinophilic syndrome.

21 January 2018

1 reference

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

21 January 2018

1 reference

Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils.

21 January 2018

1 reference

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

21 January 2018

1 reference

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.22062

1 reference

25 August 2017

1 reference